Skip to content

Axsome Therapeutics

US · AXSM #1533 by market cap Listed 2015
129.36 -6.32 -4.66%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:30

Recent news

  • Rating change
    Truist Financial Initiates Axsome Therapeutics(AXSM.US) With Buy Rating, Announces Target Price $285
    Market Newswire · 2026/9/23
  • Rating change
    H.C. Wainwright Reaffirms Their Buy Rating on Axsome Therapeutics (AXSM)
    TipRanks · 2026/9/22
  • Rating change
    Deutsche Bank Maintains Axsome Therapeutics(AXSM.US) With Buy Rating, Cuts Target Price to $267
    Market Newswire · 2026/9/29
  • Rating change
    Morgan Stanley Maintains Axsome Therapeutics(AXSM.US) With Hold Rating, Maintains Target Price $251
    Market Newswire · 2026/9/25
  • Rating change
    Needham Maintains Axsome Therapeutics(AXSM.US) With Buy Rating, Maintains Target Price $268
    Market Newswire · 2026/10/15
  • Rating change
    Wells Fargo Maintains Axsome Therapeutics(AXSM.US) With Buy Rating, Maintains Target Price $256
    Market Newswire · 2026/10/1
  • Rating change
    Piper Sandler Maintains Axsome Therapeutics(AXSM.US) With Buy Rating, Cuts Target Price to $238
    Market Newswire · 2026/10/26
  • A Quick Look at Today's Ratings for Axsome Therapeutics(AXSM.US), With a Forecast Between $220 to $256
    Market Newswire · 2026/11/4
  • Rating change
    BMO Capital Initiates Axsome Therapeutics(AXSM.US) With Buy Rating, Announces Target Price $310
    Market Newswire · 2026/10/12
  • Rating change
    Mizuho Securities Maintains Axsome Therapeutics(AXSM.US) With Buy Rating, Cuts Target Price to $284
    Market Newswire · 2026/10/29
  • A Quick Look at Today's Ratings for Axsome Therapeutics(AXSM.US), With a Forecast Between $235 to $305
    Market Newswire · 2026/11/3
  • Rating change
    Oppenheimer Maintains Axsome Therapeutics(AXSM.US) With Buy Rating, Raises Target Price to $280
    Market Newswire · 2026/10/6
  • Rating change
    Oppenheimer Maintains Axsome Therapeutics(AXSM.US) With Buy Rating, Maintains Target Price $280
    Market Newswire · 2026/10/29
  • Rating change
    RBC Capital Maintains Axsome Therapeutics(AXSM.US) With Buy Rating, Cuts Target Price to $295
    Market Newswire · 2026/10/8
  • Rating change
    RBC Capital Maintains Axsome Therapeutics(AXSM.US) With Buy Rating, Maintains Target Price $295
    Market Newswire · 2026/10/14
  • Mizuho Securities Maintains Axsome Therapeutics(AXSM.US) With Buy Rating, Cuts Target Price to $272
    Market Newswire · 2026/11/4
  • Rating change
    BofA Securities Maintains Axsome Therapeutics(AXSM.US) With Buy Rating, Maintains Target Price $276
    Market Newswire · 2026/10/9
  • H.C. Wainwright Maintains Axsome Therapeutics(AXSM.US) With Buy Rating, Maintains Target Price $290
    Market Newswire · 2026/11/9
  • Morgan Stanley Maintains Axsome Therapeutics(AXSM.US) With Hold Rating, Cuts Target Price to $223
    Market Newswire · 2026/11/13
  • Rating change
    Analysts Offer Insights on Healthcare Companies: Starling Oncology Institute (STLN), Axsome Therapeutics (AXSM) and Contineum Therapeutics, Inc. Class A (CTNM)
    TipRanks · 2026/10/14
  • Rating change
    BMO Capital Maintains Axsome Therapeutics(AXSM.US) With Buy Rating, Maintains Target Price $310
    Market Newswire · 2026/9/14
  • Rating change
    Piper Sandler Maintains Axsome Therapeutics(AXSM.US) With Buy Rating, Maintains Target Price $258
    Market Newswire · 2026/9/18
  • Rating change
    Mizuho Securities Maintains Axsome Therapeutics(AXSM.US) With Buy Rating, Maintains Target Price $316
    Market Newswire · 2026/9/12
  • Rating change
    RBC Capital Maintains Axsome Therapeutics(AXSM.US) With Buy Rating, Maintains Target Price $297
    Market Newswire · 2026/9/18
  • Rating change
    H.C. Wainwright Maintains Axsome Therapeutics(AXSM.US) With Buy Rating, Maintains Target Price $290
    Market Newswire · 2026/9/25

Headlines are aggregated automatically and are not independently verified or edited by our team.

Quote time 2026-11-20 19:30:06 · For reference only, not investment advice and not tailored to your situation.

Axsome Therapeutics discussion 0 comments

Add a comment